Literature DB >> 1432032

Treatment of recurrent metastatic medulloblastoma with intensive chemotherapy and allogeneic bone marrow transplantation.

J H Lundberg1, D E Weissman, P A Beatty, R C Ash.   

Abstract

We report here the first known case of a patient with recurrent metastatic medulloblastoma to achieve long-term disease-free survival following treatment with allogeneic bone marrow transplantation. A 27 year old white male with recurrent metastatic medulloblastoma involving lymph nodes, bone and bone marrow was treated with multi-agent chemotherapy followed by allogeneic bone marrow transplantation from an HLA-identical sibling donor. Morbidity was acceptable with moderate to severe mucositis in the immediate post transplant period and clinical grade I graft versus host disease of the skin controlled with modest doses of corticosteroids. The patient continues in unmaintained complete remission in excess of 28 months with a performance status of 100%. Allogeneic marrow transplantation following cytoreductive salvage chemotherapy is an aggressive strategy that may offer an improved likelihood of disease eradication and ultimate cure for poor prognosis patients with recurrent metastatic medulloblastoma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1432032     DOI: 10.1007/bf00172764

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  22 in total

1.  Medulloblastoma--prognostic factors and outcome of treatment: review of the Mayo Clinic experience.

Authors:  G R Garton; P J Schomberg; B W Scheithauer; E G Shaw; D M Ilstrup; C R Blackwell; E R Laws; J D Earle
Journal:  Mayo Clin Proc       Date:  1990-08       Impact factor: 7.616

2.  Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen.

Authors:  P J Tutschka; E A Copelan; J P Klein
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

3.  Cisplatin in recurrent pediatric brain tumors. A POG Phase II study. A Pediatric Oncology Group Study.

Authors:  C L Sexauer; A Khan; P C Burger; J P Krischer; J van Eys; T Vats; A H Ragab
Journal:  Cancer       Date:  1985-10-01       Impact factor: 6.860

4.  Graft-versus-leukemia reactions after bone marrow transplantation.

Authors:  M M Horowitz; R P Gale; P M Sondel; J M Goldman; J Kersey; H J Kolb; A A Rimm; O Ringdén; C Rozman; B Speck
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

5.  Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine.

Authors:  D C Crafts; V A Levin; M S Edwards; T L Pischer; C B Wilson
Journal:  J Neurosurg       Date:  1978-10       Impact factor: 5.115

6.  Etoposide (VP-16-213) in malignant brain tumors: a phase II study.

Authors:  U Tirelli; M D'Incalci; R Canetta; S Tumolo; G Franchin; A Veronesi; E Galligioni; M G Trovò; C Rossi; E Grigoletto
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

Review 7.  Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants.

Authors:  K Antman; R P Gale
Journal:  Ann Intern Med       Date:  1988-04       Impact factor: 25.391

8.  High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children.

Authors:  J C Allen; L Helson
Journal:  J Neurosurg       Date:  1981-11       Impact factor: 5.115

9.  Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents.

Authors:  H S Friedman; O M Colvin; S X Skapek; S M Ludeman; G B Elion; S C Schold; P F Jacobsen; L H Muhlbaier; D D Bigner
Journal:  Cancer Res       Date:  1988-08-01       Impact factor: 12.701

10.  Cisplatin therapy in recurrent childhood brain tumors.

Authors:  A B Khan; B J D'Souza; M D Wharam; L A Champion; L F Sinks; S Y Woo; D C McCullough; B G Leventhal
Journal:  Cancer Treat Rep       Date:  1982-12
View more
  7 in total

1.  High-dose chemotherapy followed by autologous and allogeneic peripheral blood stem cell transplantation for recurrent disseminated trilateral retinoblastoma.

Authors:  Toshihisa Tsuruta; Yasuo Aihara; Hitoshi Kanno; Chikako Kiyotani; Katsuya Maebayashi; Masako Sakauchi; Makiko Osawa; Hisaichi Fujii; Osami Kubo; Yoshikazu Okada
Journal:  Childs Nerv Syst       Date:  2011-03-19       Impact factor: 1.475

2.  Shunt-related abdominal metastases in an infant with medulloblastoma: long-term remission by systemic chemotherapy and surgery.

Authors:  A Fiorillo; G Maggi; A Martone; R Migliorati; R D'Amore; E Alfieri; N Greco; S Cirillo; I Marano
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

3.  Chemotherapeutic induction of long-term remission in metastatic medulloblastoma.

Authors:  E Leo; P G Schlegel; A Lindemann
Journal:  J Neurooncol       Date:  1997-04       Impact factor: 4.130

Review 4.  High dose chemotherapy with autologous stem cell rescue for patients with medulloblastoma.

Authors:  I J Dunkel; J L Finlay
Journal:  J Neurooncol       Date:  1996-07       Impact factor: 4.130

Review 5.  Gene therapy for PNET.

Authors:  C Raffel
Journal:  J Neurooncol       Date:  1996-07       Impact factor: 4.130

Review 6.  Management of recurrent medulloblastoma in adult patients: a systematic review and recommendations.

Authors:  Xanthoula Kostaras; Jacob C Easaw
Journal:  J Neurooncol       Date:  2013-07-23       Impact factor: 4.130

Review 7.  High dose chemotherapy with stem-cell transplantation in a metastatic medulloblastoma in an adult: a case report and review of the literature.

Authors:  P H Cottu; S Giacchetti; L Mignot; B Epardeau; B Visot; J M Extra; M Espie; M Marty
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.